Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: Time for a public health approach

The Lancet

Volumn 378, Issue 9787, 2011, Pages 282-284

  Schouten, Erik J ^a,b   Jahn, Andreas ^a,c   Midiani, Dalitso ^a   Makombe, Simon D ^a   Mnthambala, Austin ^a   Chirwa, Zengani ^a,c   Harries, Anthony D ^d,e   Van Oosterhout, Joep J ^f   Meguid, Tarek ^g   Ben Smith, Anne ^h   Zachariah, Rony ⁱ   Lynen, Lutgarde ^j   Zolfo, Maria ^j   Van Damme, Wim ^j   Gilks, Charles F ^k,l   Atun, Rifat ^m,n   Shawa, Mary ^o   Chimbwandira, Frank ^a  

^a MINISTRY OF HEALTH   (Malawi)

^b Management Sciences for Health   (Malawi)

^c UNIVERSITY OF WASHINGTON   (United States)

^d INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f UNIVERSITY OF MALAWI   (Malawi)

^g KAMUZU CENTRAL HOSPITAL   (Malawi)

^h Maame Akua   (Malawi)

ⁱ Operational Research Unit   (Luxembourg)

^j INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^k UNAIDS   (India)

^l IMPERIAL COLLEGE LONDON   (United Kingdom)

^m IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁿ TUBERCULOSIS AND MALARIA   (Switzerland)

^o Office of the President and Cabinet   (Malawi)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; TENOFOVIR; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; CD4 LYMPHOCYTE COUNT; CHILD HEALTH CARE; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EUROPE; FIRST TRIMESTER PREGNANCY; HEALTH CARE FACILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MALAWI; MATERNAL MORTALITY; MOTHER CHILD RELATION; PRACTICE GUIDELINE; PREGNANT WOMAN; PRENATAL CARE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; SECOND TRIMESTER PREGNANCY; TERATOGENICITY; TREATMENT DURATION; TUBERCULOSIS; UNITED STATES; VIRUS TRANSMISSION;

EID: 79960346745     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)62303-3     Document Type: Note

References (22)

1. WHO Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach (2010 version) 2010 World Health Organization Geneva
2. WHO Antiretroviral therapy for HIV Infection in adults and adolescents: recommendations for a public health approach (2010 version) 2010 World Health Organization Geneva
3. UNAIDS 09 AIDS epidemic update http://data.unaids.org/pub/Report/2009/ JC1700-Epi-Update-2009-en.pdf November 2009 (accessed Jan 24, 2010).
4. LM Mofenson Prevention in neglected subpopulations: prevention of mother-to-child transmission of HIV infection Clin Infect Dis 50 suppl 3 2010 S130 S148
5. HIV Unit, Ministry of Health, Malawi Antiretroviral therapy http://www.hivunitmohmw.org/Main/AntiretroviralTherapy (accessed March 16, 2011).
6. CF Gilks, S C (Pubitemid 44142772)
7. AD Harries, EJ Schouten, E Libamba Scaling up antiretroviral treatment in resource-poor settings Lancet 367 2006 1870 1872 (Pubitemid 43833194)
8. WHO Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2010 2010 World Health Organization Geneva
9. DART Trial Team Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial Lancet 375 2010 123 131
10. RM Granich, CF Gilks, C Dye, KM De Cock, BG Williams Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model Lancet 373 2009 48 57
11. WHO World health statistics 2009 2009 World Health Organization Geneva
12. L Myer, RJ Carter, M Katyal, P Toro, WM El-Sadr, EJ Abrams Impact of antiretroviral therapy on incidence of pregnancy among HIV-infected women in Sub-Saharan Africa: a cohort study PLoS Med 7 2010 e1000229
13. National Statistical Office ORC MACRO Malawi demographic and health survey 2004 2005 National Statistics Office and ORC MACRO Calverton, MD
14. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group CD4+ count-guided interruption of antiretroviral treatment N Engl J Med 355 2006 2283 2296
15. S Sutcliffe, TE Taha, NI Kumwenda, E Taylor, GN Liomba HIV-1 prevalence and herpes simplex virus 2, hepatitis C virus, and hepatitis B virus infections among male workers at a sugar estate in Malawi J Acquir Immune Defic Syndr 31 2002 90 97
16. JW Hargrove, JH Humphrey Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe AIDS 24 2010 F11 F14
17. SD Lawn, L Meyer, D Edwards, LG Bekker, R Wood Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy AIDS 23 2009 1717 1725
18. AD Harries, R Zachariah, EL Corbett et al. The HIV-associated tuberculosis epidemic - when will we act? Lancet 375 2010 1906 1919
19. When To Start Consortium Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies Lancet 373 2009 1352 1363
20. D Donnell, JM Baeten, J Kiarie et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis Lancet 375 2010 2092 2098
21. Campaign for access to essential medicines, Médicins sans Frontires Untangling the web of antiretroviral price reductions: tenofovir disoproxil fumarate/lamivudine/efavirenz (TDF/3TC/EFV) http://utw.msfaccess.org/ drugs/tdf-3tc-efv (accessed Jan 24, 2010).
22. N Ford, L Mofenson, K Kranzer et al. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts AIDS 24 2010 1461 1470